Twenty state attorneys general sued a group of generic drug companies Thursday, accusing them of conspiring to fix prices on an antibiotic and a diabetes medication.
The suit comes a day after price-fixing charges against former executives at one of the drugmakers were unsealed in a Justice Department antitrust probe.
The attorneys general, including New York’s Eric Schneiderman and Connecticut’s George Jepsen, alleged in a suit filed in Connecticut federal court that Heritage Pharmaceuticals; Aurobindo Pharma USA; Citron Pharma; Mayne Pharma; Mylan Pharmaceuticals; and Teva Pharmaceuticals USA, conspired to manipulate prices for doxycycline hyclate, an antibiotic, and glyburide, used in the treatment of diabetes.
On Wednesday, federal prosecutors unsealed charges against Heritage’s former chief executive and former president, alleging they conspired with competitors to fix prices and allocate customers for the same two drugs.
Heritage has said it fired those executives and is cooperating with the Justice Department.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK’s CMA Investigates Education Software Company for Market Abuse
May 14, 2024 by
CPI
Schumer Urges FTC Caution on Chevron’s $53B Hess Deal Over Gas Price Fears
May 14, 2024 by
CPI
Amazon Urges US Judge to Block FTC Probe into Data Preservation
May 14, 2024 by
CPI
Colorado Makes History: First State to Enact Comprehensive AI Legislation
May 14, 2024 by
CPI
Class Action Settlement Reached in Cheerleading Monopoly
May 14, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI